Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)

Inclusion criteria: * Signed informed consent * Histological verified primary glioblastoma multiforme * No prior therapy for GBM, except for primary surgical resection or biopsy * PS 0-2 * Age \> 18 * Expected survival \> 3 months * Adequate liver, renal and bone-marrow function, determined as: * Thrombocytes \> 100 x 109/liter * Hemoglobin \>6.2 mmol/liter * Leukocytes \> 3 x 109/liter * Neutrophil granulocytes \> 1.5 x 109/liter * ASAT and/or ALAT \< 3 x upper normal limit * Bilirubin \< 1.5 x upper normal limit * Serum-creatinin \< upper normal limit or glomerular filtration rate \>60 ml/min (corrected for age) determined by measurement of clearance of Cr-EDTA * APTT \< upper normal limit * INR \< upper normal limit * Fertile women of childbearing age must use proper anti-conception (oral contraceptives, IUD and/or condom). Fertile men must use condom * No sign of cerebral bleeding on cerebral MR-scanning at baseline. Exclusion criteria: * Previous therapy of GBM, including radiotherapy and the use of biological " targeted" drug, e.g. drugs targeted against the VEGF- or EGFR pathway * Concurrent use of medication that can affect the interpretation of the results from the study, e.g. use of immunosuppressive drugs, except corticosteroids * Conditions (medical, social or physical) that may compromise proper information and/or follow-up * Other concurrent or previous cancer within 5 years, except adequately treated basal or planocellular skin cancer, or cervical carcinoma in situ * Significant heart disease (according to the New York Heart Association class II or more severe), clinically significant arrhythmia or unstable angina pectoris/acute myocardial infarction within last 6 months * Clinical significant peripheral arterial disease * Known or suspected disorders of coagulation or concurrent therapy with ASA, NSAID or clopidogrel * Major surgery, open biopsy or greater trauma, or expectations thereof, within 28 days prior to start of therapy * Minor surgery or needle biopsy, or expectations thereof, within 7 days prior to start of therapy * Known or suspected abdominal fistulas, gastrointestinal perforations or intra-abdominal abscesses within 6 months prior to start of therapy * Chronic inflammatory intestinal disease and/or intestinal obstruction * Known or active HIV or Hepatitis B/C infection * Concurrent ongoing significant infection or diabetes mellitus not adequately controlled medically * Clinically significant non-healing ulcers * Active ventricular or duodenal ulcers within 6 months prior to start of therapy * Recent bone-fracture (\<3 months) * Pregnancy or lactation * Need for systemic anticoagulant therapy at time of start of therapy * Blood pressure \> 150/100 mmHg (patients are allowed to receive proper antihypertensive medication) * Proteinuria ≥ 1 gram/day * Known allergy toward irinotecan (or related substance) or vehicle * Known allergy toward temozolomide (or related substance) or vehicle * Known allergy toward bevacizumab (or related substance) or vehicle